A former adversary of the DEA and HHS now shapes federal drug reform as Deputy General Counsel, steering executive orders and clinical access.

A Bay Area nonprofit is building an IRB-backed study of intramuscular ketamine-assisted psychotherapy for postpartum depression, with breastfeeding and access front and center.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

Oregon pauses a proposed psilocybin fee increase, California earmarks $4.7M for psychedelic research, and the DEA moves to schedule five tryptamines—here’s why it matters.

From frankincense to mandrake, Scripture names plants with mind-altering potential. Here’s what shows up in the text—and how DMV readers can think about it today.

Federal lobbying hit record highs in Q2 2026 while the DEA targets tryptamines and Oregon reconsiders psilocybin program fees.

After public feedback, Oregon’s health regulators shelved a proposal to double psilocybin licensing fees and will restart rulemaking, with other changes eyed for 2027.

A new Psychedelic Alpha podcast surveys D.C.’s psychedelic moment, the FDA’s evolving medical framework, and New Zealand’s MDMA prescribers—here’s why the DMV should care.

A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

Splashy headlines about psilocybin and LSD often outpace the science. Here’s how to read studies critically—and what that means for DMV drug policy conversations.

UCSF neuroscientist Robin Carhart-Harris uses brain imaging and clinical trials to explore how psychedelics alter cognition and mood — and what that could mean for patients in the DMV.

A new federal push to speed psychedelic therapies highlights ibogaine and VA trials, but funding cuts, workforce gaps, and ethics could slow real-world access.

A tense exchange at Psychedelic Culture put ethics of research in conflict zones under a microscope—raising questions for psychedelic science, patient access, and the DMV.

Exploring the science behind messianic experiences on psychedelics, clinical findings, and safe integration for DMV wellness seekers.

New York's amended Medical Psilocybin Act outlines clinical access rules, offering a therapeutic model for the East Coast and DMV region.

A close look at new research on psychedelics, authoritarian attitudes, and what an April executive action could mean—plus why DMV cannabis rules are a separate lane.

A plain-language guide to 5‑MeO‑DMT—the “God Molecule”—covering effects, risks, early research, legality, and what DC, Maryland, and Virginia residents should know now.

Discover the legal battles, scientific testing disputes, and regulatory developments surrounding the Church of Sacred Synthesis sacrament.

Navigating intense ceremonial connections requires grounded communication, emotional boundaries, and real-world relationship integration.

Psychedelic Alpha spotlights Kimon de Greef’s look at 5‑MeO‑DMT’s ascent from Sonora to pharmaceutical interest. Here’s what DMV readers should watch and why it matters.